Theravance Biopharma (TBPH) Misses Q4 EPS by 31c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
Needham & Company Reiterates Buy on Theravance Biopharma (TBPH) Following Conference Call
February 28, 2017 7:07 AM ESTNeedham & Company reiterated a Buy rating and $40.00 price target on Theravance Biopharma (NASDAQ: TBPH) following the company's 4Q conference call.
Analyst Alan Carr commented, "Theravance mgmt hosted a 4Q16 conference call late yesterday to provide a corporate update. We note several expected... More
